LIC Mutual Fund
When comparing, both lines start at 100. Tradinity's reference for the category: a total-return index (dividends reinvested). The fund's declared benchmark (BSE Healthcare - TRI) is not available to us as a series.
This is an IDCW (dividend) option: it pays cash out of its NAV, so returns computed from the NAV alone would understate what an investor earned. See the Growth option of the same plan for performance.
Computed from this fund's actual NAVs. A SIP buys at the first NAV of each month and is valued at the latest NAV. Past returns do not guarantee future ones.
Weights are % of the scheme's assets from the latest month-end disclosure available to Tradinity. Shown from the Direct plan of this fund, which holds the same portfolio. The feed carries weights only: no quantities or rupee values.
Valuation ratios are weighted over the holdings we can match to a company (harmonic mean for P/E) and are withheld when they cover under half the portfolio.
| Equity | 98.52% |
| Cash & Equivalents | 1.48% |
Click a sector to filter the holdings below (holdings map to our sector list where the company is known).
| Holding | Sector | Weight | 3M change | P/E |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | Healthcare | 10.09% | -0.46 pp | 143.5 |
| Divi's Laboratories Ltd | Healthcare | 9.29% | 2.12 pp | 83.0 |
| Torrent Pharmaceuticals Ltd | Healthcare | 6.45% | -0.10 pp | 77.7 |
| Neuland Laboratories Limited | Healthcare | 6.38% | 0.64 pp | 56.5 |
| Apollo Hospitals Enterprise Limited | Healthcare | 6.23% | -0.54 pp | 73.1 |
| Navin Fluorine International Ltd | Chemicals | 5.65% | 0.07 pp | 74.9 |
| Aurobindo Pharma Limited | Healthcare | 5.17% | -0.13 pp | 37.5 |
| Aster DM Quality Care Limited | Healthcare | 4.82% | 1.64 pp | 205.8 |
| Zydus Lifesciences Ltd | Healthcare | 4.79% | -0.32 pp | 32.6 |
| Gland Pharma Ltd | Healthcare | 3.93% | 0.14 pp | 34.4 |
| Fortis Healthcare Ltd | Healthcare | 3.79% | -0.66 pp | 255.5 |
| Global Health Ltd | Healthcare | 3.19% | 0.03 pp | 74.4 |
| IPCA Laboratories Ltd | Healthcare | 3.18% | 0.13 pp | 39.8 |
| Metropolis Healthcare Ltd | Healthcare | 3.17% | 0.41 pp | 28.1 |
| Cohance Lifesciences Ltd | Healthcare | 2.92% | 2.92 pp | 96.3 |
| Mankind Pharma Ltd | Healthcare | 2.89% | 0.53 pp | 46.9 |
| Glenmark Pharmaceuticals Limited | Healthcare | 2.88% | 0.03 pp | 316.1 |
| Artemis Medicare Services Ltd | Healthcare | 2.88% | 0.20 pp | 45.3 |
| Max Healthcare Institute Limited | Healthcare | 2.55% | 0.51 pp | 124.3 |
| Dr. Agarwal's Health Care Limited | Healthcare | 2.54% | 0.49 pp | 334.0 |
| Biocon Limited | Healthcare | 2.54% | -0.33 pp | 596.5 |
| Onesource Specialty Pharma Ltd | Healthcare | 2.21% | -0.46 pp | 358.6 |
| Treps | — | 1.58% | -3.66 pp | — |
| Syngene International Ltd | Healthcare | 0.97% | 0.97 pp | 62.8 |
This is a paid feature
Comparing more months of this fund's own portfolio history is available on paid plans.
Sign inExpense ratio by month: Oct 25 2.45% · Nov 25 2.45% · Dec 25 2.45% · Jan 26 2.44% · Feb 26 2.36% · Mar 26 2.36% · Apr 26 2.44% · May 26 2.44% · Jun 26 2.84% · Jul 26 2.72% · Aug 26 2.72% · Sep 26 2.67%
Nil, If units of the Scheme are redeemed or switched out up to 12% of the units (the limit) within 90 days from the date of allotment. 1% of the applicable NAV, If units of the scheme are redeemed or switched out in excess of the limit within 90 days from the date of allotment. Nil, If units of scheme are redeemed or switched out after 90 days from the date of allotment.
The objective of the Scheme is to achieve long term capital appreciation by predominantly investing in equity and equity related instruments of companies engaged in Healthcare and Allied sectors. There is no assurance that the investment objective of the Scheme will be achieved.
Fund house: website · factsheets · monthly portfolio · annual report
Not available: Morningstar rating (proprietary). "NAV history from" is the first NAV we hold.
Returns are computed by Tradinity from each scheme's own published NAV, so they are net of the fund's expenses. Periods over one year are annualised (CAGR). Past performance does not indicate future returns. Only Growth-option schemes are ranked: an IDCW scheme pays cash out of its NAV, so its NAV understates what an investor earned.
